SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as its community rallies around the project's consistent grind and recent milestones, fueled by a strong belief in its potential within the meme coin space on the Solana network. The community is actively discussing the coin's path to number one trending and eagerly anticipating upcoming utility releases, solidifying their conviction in Brokecoin's long-term prospects. With a focus on community engagement and transparency, Brokecoin aims to differentiate itself in the crowded altcoin market.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crowd is excited about Crow With Knife ($CAW.X), a meme token, with community members highlighting its fully circulated supply, active community, and multichain functionality across $SOL.X, BSC, $CRO.X, and $ETH.X. There is also discussion around its deflationary burn mechanism and partnerships.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as the community discusses its potential inclusion in the S&P 500, with the official announcement expected soon; the addition could lead to increased visibility and investment, though some investors are wary of a potential "sell the news" event. Community members are also weighing in on the platform's user experience, active trader focus, and comparison to competitors, while others are still referencing the company's involvement in the 2020 GME situation. Upcoming catalysts such as the Robinhood summit next week and anticipated Fed rate cuts are adding to the speculative buzz.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors assess its potential amid the AI-driven automation landscape, with discussions focusing on its growth prospects and recent analyst ratings. Community members are debating whether the company is undervalued, citing its strong market position and partnerships, while others express concern over insider selling and the stock's historical performance. Speculation about a potential buyout is also circulating, adding to the heightened interest in PATH.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind is trending as investors discuss its collaboration with United Therapeutics to develop a second inhaled therapy, sparking speculation about new revenue streams and a potential pipeline boost. The community is weighing the potential impact of this partnership alongside the recent scPharmaceuticals acquisition, considering both the opportunities and MannKind's historical performance. Bullish sentiment is fueled by analyst price target updates and anticipation of upcoming catalysts, though some remain wary, pointing to the company's past struggles with execution.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is trending due to its inclusion in the S&P 500, generating significant after-hours buzz and speculation about its future performance. While some community members are celebrating potential gains, others caution about overvaluation and potential insider selling. The inclusion has sparked discussions about the 'index effect' and its impact on the stock's trajectory.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending due to concerns and discussions surrounding a potential link between Tylenol, one of its key products, and autism, sparked by comments from RFK Jr., leading to a sharp drop and community debate on the validity of the claims and potential buying opportunities. Traders are weighing the headline risk against the company's fundamentals, resulting in high trading volume and options activity. The stock is also being discussed in the context of broader sector concerns and potential activist investor activity.

Katapult Holdings, Inc. is an e-commerce focused financial technology company. The firm is engaged in the provision of e-commerce point-of-sale lease-purchase options for nonprime U.S. consumers. It offers its customers a lease purchase transaction processing system with no long-term obligation and options for ownership. The company was founded in August 2019 and is headquartered in Plano, TX.

Katapult Holdings Inc

KPLT is trending due to a potential turnaround and positive Q4 performance update, with gross originations growing double-digits year-over-year. Community members are discussing the low market cap relative to revenue and comparing it to other players in the BNPL space like SEZL, with some expressing optimism for a significant price increase. Some investors are also excited about the potential for a short squeeze, and a renewed credit facility.

Ramaco Resources, Inc. engages in the operation and development of coal mining properties. The firm deals with metallurgical coal in central and southern West Virginia, southwestern Virginia and southwestern Pennsylvania. Its portfolio consists of Elk Creek, Berwind, RAM Mine, and Knox Creek. The company was founded by Randall W. Atkins in August 2015 and is headquartered in Lexington, KY.

Ramaco Resources Inc - Ordinary Shares - Class A

Ramaco Resources Inc

Smith & Wesson Brands, Inc. is a holding company, which engages in the manufacture, design, and provision of firearms. Its portfolio includes handguns, long guns, handcuffs, suppressor, and other firearm-related products. The firm's brands are Smith & Wesson, M&P, Thompson/Center Arms, and Gemtech. The company was founded by Horace Smith and Daniel Baird Wesson in 1852 and is headquartered in Maryville, TN.

Smith & Wesson Brands Inc

Smith & Wesson (SWBI) is trending as investors discuss the implications of recent quarterly results and forward guidance. While some community members point to an attractive valuation and dividend yield, others express concern over the balance sheet, revenue, and overall market conditions affecting the firearms industry. Community members are also monitoring potential catalysts such as political events and military contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting...

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements PR Newswire NEW YORK, Jan. 24, 2025 NEW YORK, Jan. 24, 2025...

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent...

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 PR Newswire NEW YORK, Jan. 17, 2025 NEW YORK, Jan. 17...

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries PR Newswire NEW YORK, Jan. 8, 2025 The Company affirms...

Hoth Therapeutics Inc., a micro-cap biotech company, saw its stock price surge over 200% on Tuesday to become the top gainer across U.S. exchanges.&nbsp;Trading volume skyrocketed to 665 times its daily average, driven by positive interim data from its Phase 2a trial of HT-001, a therapy targeting skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitors in cancer patients.The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.&nbsp;Additionally, 66% of patients reported reduced pain and itching, improving their quality of life without any treatment-related adverse effects, the company said.CEO Robb Knie described the results as a “significant milestone,” emphasizing the potential of HT-001 to alleviate debilitating skin conditions while enabling patients to continue life-saving cancer treatments.D. Boral Capital echoed this optimism, highlighting the therapy’s potential to revolutionize care for patients enduring severe side effects from cancer treatments.&nbsp;The brokerage reiterated its ‘Buy’ rating and maintained a $5 price target on Hoth’s shares, implying a near doubling from current levels.Retail investors on Stocktwits rallied behind the news, with chatter indicating overwhelmingly bullish commentary.&nbsp;One user predicted a further surge to $10, urging users to “buy cheap now.”&nbsp;<stembedurl>https://stocktwits.com/Aone7Prof/message/599175761</stembedurl>Another emphasized the company’s strong position, pointing out its debt-free status and cash reserves.<stembedurl>https://stocktwits.com/Millionaire2/message/599174136</stembedurl><stembedurl>https://stocktwits.com/JBG99/message/599173146</stembedurl>Hoth’s pipeline includes therapies for dermatological disorders such as eczema, psoriasis, chronic wounds, and acne.&nbsp;The company’s stock has gained nearly 80% over the past year.The successful Phase 2a trial positions Hoth to attract interest from larger players in the oncology and dermatology sectors.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited 

The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.

Equity

The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.


Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001...

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop...

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset PR Newswire NEW YORK, Nov. 20, 2024 NEW...

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway Hoth Therapeutics Awarded Key US Patent for...

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

HOTH
Hoth Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest HOTH News

HOTH Hoth Therapeutics Inc